Cigna (NYSE:CI) Stock

Cigna

Cigna Group

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of September 2024.

Unitedhealthcare,Headquarters,In,Minnetonka,,Minnesota,,Usa,,May,5,,2023.,Unitedhealthcare

Large Cap

News

Health Care

Legal

Movers

Media

Trading Ideas

General

The Justice Department is investigating UnitedHealth&#39;s Medicare billing practices, focusing on diagnoses that led to higher federal payments. The probe follows reports that the company received billions for questionable diagnoses in its Medicare Advantage plans.

DOJ Investigates UnitedHealth, Probe Accuses Of Inflating Medicare Diagnoses


([content-module:CompanyOverview, NYSE:HUM)
Health insurance giant Humana Inc. (NYSE:HUM) stock initially rose in reaction to its fourth quarter of 2024 earnings report despite posting losses.
The medical sector

Humana Gains Despite Medicare Advantage Losses—What&#39;s the Catch?



Leading health insurer Cigna Group Inc. (NYSE:CI) was praised for having the foresight to divest its Medicare Advantage (MA) business before rising acute care utilization rates would impact its medical care ratio (MCR)

Cigna Misses EPS: What It Means for the Health Insurance Industry

The Cigna Group

Citizens, Inc. Class A Common Stock ($1.00 Par)

Citizens Inc

CHINA MENGNIU DAIRY CO by China Mengniu Dairy Co., Ltd.

China Mengniu Dairy Co Ltd

CHINA MENGNIU DARY UN/ADR by China Mengniu Dairy Co., Ltd.

CHAMPION IRON LTD by Champion Iron Limited

Champion Iron Ltd

CHINA SCORE INC by China Score, Inc.

BanColombia SA

COMML INTL BK S/ADR by Commercial International Bank Ltd.

Commercial International Bank (Egypt) CIB

CIB MARINE BANCSHARES by CIB Marine Bancshares, Inc.

CIB Marine Bancshares Inc

COMMUTY INV BANCORP INC by Community Investors Bancorp, Inc.

Community Investors Bancorp Inc

First Trust NASDAQ Cybersecurity ETF

CIBL Inc

CION Investment Corporation 7.50% Notes due 2029

CHINA CONSTR BANK H by China Construction Bank Corp.

China Construction Bank Corp

CHINA CONSTR BK UNSP/ADR by China Construction Bank Corp.

SMS ALTERNATIVES INC by SMS Alternatives Inc.

SMS Alternatives Inc

COSCO SHIPPING HLDGS CO by COSCO SHIPPING Holdings Co Ltd.

COSCO SHIPPING Holdings Co Ltd

COSCO SHP HLDG UNSP/ADR by COSCO SHIPPING Holdings Co Ltd.

CONCEPCION INDUSTRIAL CRP by CONCEPCION INDUSTRIAL CORP

Victory Portfolios II VictoryShares International High Div Volatility Wt

CLAL INSURANCE ENTERPRISE by CLAL INSURANCE ENTERPRISES HOLDINGS LTD.

Ciena Corp

CHieru Co Ltd

CORPORACION INTERAMER B by Corporacion Intramericano Entretenimiento S.A.

Corporacion Interamericana de Entretenimiento SAB de CV

MFS Intermediate High Income Fund Common Stock

Mfs Intermediate High Income Fund

Cipher Mining Inc

Comp En De Mn Cemig ADS American Depositary Shares

Cia Energetica DE Minas Gerais - Cemig

Comp En De Mn Cemig ADS American Depositary Receipts

Colliers International Group Inc. - Subordinate Voting Shares

Colliers International Group Inc

CI Games SE

CHINA MERCHANTS BK CO H by China Merchants Bank Co., Ltd.

China Merchants Bank Co Ltd

CHINA MRCHNTS BK UNSP/ADR by China Merchants Bank Co., Ltd.

CB INDUS PRODUCT HLDG BHD by CB Industrial Product Holding BHD

BlackRock Enhanced Large Cap Core Fund, Inc. Common Stock

Blackrock Enhanced Cap&Inc Fund, Inc

CITIC SECURITIES CO LTD H by Citic Securities Co., Ltd.

CITIC Securities Co Ltd

CITIC SECURITIES UNSP/ADR by Citic Securities Co., Ltd.

TIANCI INTERNATIONAL INC by Tianci International Inc.

Tianci International Inc

Credit Suisse Asset Management Income Fund, Inc. Common Stock

Credit Suisse Asset Mgmt Income Fund Inc

VictoryShares International Volatility Wtd ETF

CHINA LIFE INS CO H SHS by China Life Insurance Company Limited

China Life Insurance Co Ltd

CAROLINA MILLS INC by Carolina Mills, Inc.

Chimera Investment Corporation Common Stock

Chimera Investment Corp

CIMB GROUP HLDGS BHD ORD by CIMB Group Holdings BHD

CIMB Group Holdings Bhd

CIMC ENRIC HLDGS LTD ORD by CIMC Enric Holdings Ltd.

CIMC Enric Holdings Ltd

Chimera Investment Corporation 9.000% Senior Notes due 2029

Chimera Investment Corporation 9.250% Senior Notes due 2029

CIMAREX ENERGY 8 1/8 PFD by Cimarex Energy Co.

Chimera Investment Corporation 8.00% Series A Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 8.00% Series B Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 7.75% Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 8.00% Series D Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

CHINA INDUSTRIAL GRP INC by China Industrial Group, Inc.

China Industrial Group

Cincinnati Financial Corporation - Common Stock

Cincinnati Financial Corp

Cingulate Inc

COINSILIUM GROUP LTD ORD by Coinsilium Group Ltd.

Coinsilium Group Ltd

CHINA TAIPING INS HLD ORD by China Taiping Insurance Holdings Co Ltd.

China Taiping Insurance Holdings Co Ltd

CI&T Inc

CRUCIAL INNOVATIONS CORP by CRUCIAL INNOVATIONS CORP.

City Office REIT Inc

CREATE MEDIC CO LTD by Create Medic Company Ltd.

Create Medic Co Ltd

CION Invt Corp

CENTRAL IRON ORE LIMITED by CENTRAL IRON ORE LIMITED

Central Iron Ore Ltd

Cielo SA ADR

City Office REIT, Inc. 6.625% Series A Cumulative Redeemable Preferred Stock

CORRELATE ENERGY CORP by Correlate Energy Corp.

Correlate Energy Corp

JPMorgan Exchange-Traded Fund Trust Sustainable Consumption ETF

Cirus Foundation

CirTran Corp

Ciscom Corp

CHINA STEEL CP S/ADR 144A by China Steel Corp.

China Steel Corp

CISO Global Inc

C3is Inc

CHINA STEEL CORP S/GDR by China Steel Corp.

COSCO SHIPPING DEV CO LTD by Cosco Shipping Development Co Ltd.

Cosco Shipping Development Co Ltd

COSCO SHIP DEV UNSP/ADR by Cosco Shipping Development Co Ltd.

CARTICA ACQUISITION CORP L ASHS

CARTICA ACQUISITION CORP USD 1 CL A SHS & 1/2 RED WT EXP

CARTICA ACQUISITION CORP RED WTS

CRITICAL INFRASTUCTRE TCH by Critical Infrastructure Technologies Ltd.

Critical Infrastructure Technologies Ltd

AVALON CORRECTIONAL INC by Avalon Correctional Services, Inc.

Manchester City Fan Token

CITIZENS BANCSHARES CP SC by Citizens Bancshares Corp South Carolina

Citizens Bancshares Corp

Civilization

Civista Bancshares Inc

Civitas Resources Inc

Civitas Resources Inc Warrants (20/01/2026)

Civitas Resources Inc Warrants (20/01/2025)

CTR INVTS&CNSLTNG INC by CTR Investments & Consulting, Inc.

CTR Investments & Consulting Inc

CHINA INDL WASTE MGMT INC by China Industrial Waste Management, Inc.

China Industrial Waste Management Inc

CITZNS FINCL CORP W VA by Citizens Financial Corp. (WV)

Citizens Financial Corp WV

Compx International Inc

CaixaBank SA

CI Financial Corp

COMPASS EMP FDS TR DEVELOPED 500 ENHANCED VOLATILITY WEIGHTED INDEX ETF

CITZNS HOLDINGS CO MISS by Citizens Holding Co.

Citizens Holding Co

The Justice Department has reportedly launched a civil fraud investigation into UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Medicare billing practices.
The probe began in recent months and will examine UnitedHealth&#8217;s Medicare Advantage plans and physician groups following reports that the company received billions in federal payments for questionable diagnoses.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43065141/analysts-maintain-optimism-for-unitedhealth-despite-mixed-q4-results" rel="noreferrer noopener">UnitedHealth&#8217;s Strong Member Loyalty Powers Analyst Growth Forecasts</a>
The insurance giant is already under scrutiny. In January, the Federal Trade Commission released a second interim staff report detailing significant price markups on specialty generic drugs by&nbsp;UnitedHealth&#8217;s pharmacy benefit management unit along with&nbsp;CVS Health Corp.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) CVS Caremark and&nbsp;Cigna Corp.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) <a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/43010888/ftc-says-unitedhealth-cvs-cigna-make-billions-via-pbms-on-specialty-drugs" rel="noreferrer noopener">Express Scripts</a>.
The Wall Street Journal <a target="_blank" href="https://www.wsj.com/health/healthcare/unitedhealth-medicare-doj-diagnosis-investigation-66b9f1db?mod=latest_headlines" rel="noreferrer noopener">reported</a> that Medicare paid UnitedHealth substantial sums based on diagnoses added to patients&#8217; records, some of which doctors said were irrelevant or undocumented.
The WSJ report&#8217;s analysis of Medicare data from 2019 to 2021 found that UnitedHealth-employed doctors significantly increased the number of lucrative diagnoses for patients in the company&#8217;s Medicare Advantage plans.
Additionally, some diagnoses were added without physician treatment, including through in-home nurse visits, leading to an extra $8.7 billion in federal payments in 2021.
Each visit by UnitedHealth-employed nurses was valued at an average of $2,735 in additional government reimbursements.
The WSJ report added that UnitedHealth has defended its Medicare billing practices, arguing that they lead to more accurate diagnoses, improve patient care, and reduce healthcare costs. The company has previously stated that it performs well in Medicare audits and has disputed the Journal&#8217;s findings.
UnitedHealthcare, one of the largest health insurers in the U.S. with over 50 million members, has faced ongoing criticism over its <a target="_blank" href="https://www.benzinga.com/24/12/42365853/unitedhealthcare-faces-tough-questions-following-insurance-business-ceos-tragic-death" rel="noreferrer noopener">claim denial practices</a>.
A Senate investigation earlier this year concluded that Medicare Advantage providers, including UnitedHealthcare, intentionally denied claims to increase profits.
As per a recent media report, UnitedHealthcare, the insurance arm of&nbsp;UnitedHealth, is reportedly offering some employees in its benefits operations unit a chance to take a buyout if they <a target="_blank" href="https://www.benzinga.com/25/02/43829064/unitedhealthcare-offers-voluntary-buyouts-possible-layoffs-if-targets-not-met-cnbc" rel="noreferrer noopener">resign by March 3</a>.
In a social media <a target="_blank" href="https://x.com/BillAckman/status/1892912458840547554" rel="noreferrer noopener">post</a>, investor Bill Ackman said,&#8221; When a company, in this case United Healthcare, attacks its critics, the probability that it has committed fraud or is guilty of a crime increases substantially.&#8221;
&#8220;My psychological short here is paying off and I would avoid this stock,&#8221; Ackman added.
Price Action: UNH stock was down 10.2% at $451.36&nbsp;during the premarket session at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43851537/centerpoint-energy-stays-on-track-eps-rises-25-grid-upgrade-planned-and-more" target="_blank" rel="noreferrer noopener">CenterPoint Energy Stays On Track: EPS Rises 25%, Grid Upgrade Planned And More</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock.com

Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 20 years by 3.61% on an annualized basis producing an average annual return of 11.95%. Currently, Cigna has a market capitalization of $78.60 billion. 
Buying $100 In CI: If an investor had bought $100 of CI stock 20 years ago, it would be worth $963.37 today based on a price of $287.08 for CI at the time of writing.
<h3>Cigna's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738960209_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Truist Securities analyst David Macdonald maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Buy and lowers the price target from $390 to $375.

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Cigna, Lowers Price Target to $375

Wells Fargo analyst Stephen Baxter maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Equal-Weight and lowers the price target from $370 to $341.

Wells Fargo Maintains Equal-Weight on Cigna, Lowers Price Target to $341

UBS analyst Kevin Caliendo maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Buy and lowers the price target from $410 to $390.

UBS Maintains Buy on Cigna, Lowers Price Target to $390

Piper Sandler analyst Jessica Tassan reiterates Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and lowers the price target from $394 to $348.

Reiteration

Piper Sandler Reiterates Overweight on Cigna, Lowers Price Target to $348

Cigna Healthcare, the health benefits division of The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), announced the first set in a series of planned actions to improve the health care experience for patients and physicians. The actions are part of a multi-year commitment by The Cigna Group to make the health care experience simpler and more transparent for the millions of customers it serves. &nbsp;
"We owe it to our customers to make the health care system work better – and Cigna Healthcare has an important role to play," said Bryan Holgerson, president, U.S. Employer, Cigna Healthcare. "We are working to make it easier for customers to get the care they need and to resolve challenges faster when they arise. The actions we're announcing today represent the first step in our journey to transform the health care experience for the people we serve." &nbsp;
Today, Cigna Healthcare is announcing actions to better support its customers, including:&nbsp;&nbsp;
<h3>Expanding access to dedicated advocates for patients facing complex health conditions like cancer, stroke, or heart attack.&nbsp;</h3>
<ul>
<li>Patients with serious medical situations are suddenly faced with navigating a new world of many clinicians, hospitals, and pharmacies. To accelerate access to care and create a more seamless experience, Cigna Healthcare is doubling the number of My Personal Champion advocates, who help patients navigate every stage of their care and treatment journey. These advocates, who receive high ratings from the customers they support, assist in the resolution of unique and complex clinical, situational, or administrative needs. &nbsp;</li>
</ul>
<h3>Investing resources to help more customers quickly resolve administrative needs with prior authorization and post-care claims. &nbsp;</h3>
<ul>
<li>Cigna Healthcare is adding new concierge teams to support customers experiencing challenges with prior authorization or with claims payments. A concierge will work directly with the customer's physician to resolve any information gaps that require resolution, helping to prevent stress or confusion for the customer. Additionally, the company will introduce enhancements to the digital status tracker that patients can use for prior authorization updates.&nbsp;</li>
</ul>
<h3>Accelerating and simplifying the process for physicians to submit claims and prior authorization requests.&nbsp;&nbsp;</h3>
<ul>
<li>One of the most common reasons that a prior authorization decision is delayed is because of incomplete information in the initial submission. That's why Cigna Healthcare is expanding digital communication options for physicians, including through its provider portal or directly through the electronic medical record. This will give physicians an easier way to submit all the necessary information the first time, improving turnaround time and accuracy.&nbsp;&nbsp;</li>
</ul>
"We are committing to significantly improving the prior authorization process for patients and for those providing care," said Dr. Amy Flaster, chief medical officer, Cigna Healthcare. "We want to reduce the burden on our physician partners by making it easier to submit a complete authorization request quickly and correctly the first time, expediting the path to getting needed services approved and giving providers their time back so they can invest it in what matters most: patient care."&nbsp;
These actions will improve support for the millions of people Cigna Healthcare serves through employer-sponsored plans and the Affordable Care Act (ACA) Marketplace.&nbsp;&nbsp;

Cigna Healthcare Unveils New Initiatives to Simplify Care Access, Boost Patient Support, and Enhance Physician Processes

Deep-pocketed investors have adopted a bullish approach towards Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CI usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Cigna. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 41% leaning bullish and 41% bearish. Among these notable options, 3 are puts, totaling $371,983, and 9 are calls, amounting to $7,283,474.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $280.0 and $340.0 for Cigna, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Cigna's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Cigna's substantial trades, within a strike price spectrum from $280.0 to $340.0 over the preceding 30 days.
<h3>Cigna Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738354060_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$72.0</td>
<td>$67.6</td>
<td>$71.5</td>
<td>$280.00</td>
<td>$3.4M</td>
<td align="right">799</td>
<td>1.0K</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$68.0</td>
<td>$64.0</td>
<td>$66.0</td>
<td>$280.00</td>
<td>$2.7M</td>
<td align="right">799</td>
<td>529</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$65.0</td>
<td>$65.0</td>
<td>$65.0</td>
<td>$280.00</td>
<td>$773.5K</td>
<td align="right">799</td>
<td>0</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$23.0</td>
<td>$21.7</td>
<td>$23.0</td>
<td>$300.00</td>
<td>$230.0K</td>
<td align="right">9</td>
<td>52</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$23.8</td>
<td>$21.5</td>
<td>$22.5</td>
<td>$300.00</td>
<td>$112.5K</td>
<td align="right">9</td>
<td>52</td>
</tr>
</tbody>
</table>

<h3>About Cigna</h3>
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of September 2024.
After a thorough review of the options trading surrounding Cigna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Cigna's Current Market Status</h3>
<ul>
<li>With a volume of 2,295,051, the price of CI is up 3.96% at $294.19. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 90 days.</li>
</ul>
<h3>Professional Analyst Ratings for Cigna</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $368.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Stephens &amp; Co. keeps a Overweight rating on Cigna with a target price of $380. 
&#x2A; An analyst from Raymond James has revised its rating downward to Strong Buy, adjusting the price target to $360. 
&#x2A; An analyst from Cantor Fitzgerald has decided to maintain their Overweight rating on Cigna, which currently sits at a price target of $350. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Cigna, which currently sits at a price target of $379. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Cigna, targeting a price of $375. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cigna with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Smart Money Is Betting Big In Cigna Options

Oppenheimer analyst Michael Wiederhorn maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Outperform and lowers the price target from $400 to $375.

Oppenheimer Maintains Outperform on Cigna, Lowers Price Target to $375

Cigna Group inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) shares are rebounding Friday after dropping on Thursday following a <a href="https://www.benzinga.com/news/earnings/25/01/43337308/cigna-stock-dives-on-q4-earnings-miss-we-are-taking-corrective-actions-to-address-these-near-term-pressures">fourth-quarter earnings miss</a>.
What To Know: Cigna reported fourth-quarter revenue of $65.68 billion, exceeding analyst estimates of $63.36 billion, but missed on earnings with an adjusted EPS of $6.64 versus expectations of $7.82. The earnings shortfall was driven by higher stop-loss medical costs, which contributed to an 8% decline in adjusted income from operations.
Despite the earnings miss, revenue grew 27% year-over-year, led by increases in pharmacy benefit services and specialty care. The company also announced a $6 billion increase to its share repurchase program, bringing total authorization to $10.3 billion.
Cigna provided 2025 guidance, expecting at least $252 billion in revenue, slightly above estimates. However, full-year adjusted EPS guidance of at least $29.50 fell short of analysts&#8217; expectations of $31.50.
Shares initially dropped 11.1% on Thursday but are rebounding potentially as investors focus on management's corrective actions and long-term strategy.
CI Price Action: Cigna Group shares were up 4.97% at $297.04 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent013125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31120701/Screenshot-2025-01-31-at-12.06.30-1024x530.png" alt="" class="wp-image-760645" style="width:491px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31120701/Screenshot-2025-01-31-at-12.06.30-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31120701/Screenshot-2025-01-31-at-12.06.30-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31120701/Screenshot-2025-01-31-at-12.06.30-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31120701/Screenshot-2025-01-31-at-12.06.30.png 1167w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43396598/alphabet-shares-are-on-the-rise-today-whats-going-on">Alphabet Shares Are On The Rise Today: What&#8217;s Going On?</a></li>
</ul>
Image Via Shutterstock.

Cigna Group Shares Are On The Rise Friday: What's Going On?

Raymond James analyst John Ransom reiterates Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Strong Buy and lowers the price target from $415 to $360.

Raymond James Reiterates Strong Buy on Cigna, Lowers Price Target to $360

Stephens &amp; Co. analyst Raj Kumar maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and lowers the price target from $410 to $380.

Stephens & Co. Maintains Overweight on Cigna, Lowers Price Target to $380

WIIM

Cigna shares are trading higher, rebounding after falling Thursday on a Q4 earnings miss.

Cantor Fitzgerald analyst Sarah James maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and lowers the price target from $400 to $350.

Cantor Fitzgerald Maintains Overweight on Cigna, Lowers Price Target to $350

Morgan Stanley analyst Erin Wright maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and lowers the price target from $403 to $379.

Morgan Stanley Maintains Overweight on Cigna, Lowers Price Target to $379

Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $387.4, with a high estimate of $420.00 and a low estimate of $339.00. This current average has decreased by 4.82% from the previous average price target of $407.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738332013_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Cigna. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$339.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$390.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$394.00</td>
<td>$392.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$420.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$394.00</td>
<td>$398.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cigna. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cigna compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Cigna's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Cigna's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cigna analyst ratings.</a>
<h2>Get to Know Cigna Better</h2>
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of September 2024.
<h3>Cigna: Financial Performance Dissected</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Cigna displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 28.02%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Cigna's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 1.18%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Cigna's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.77%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Cigna's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.47%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Cigna's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.78.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Cigna: 5 Analysts Share Their Views

Barclays analyst Andrew Mok maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and lowers the price target from $420 to $339.

Barclays Maintains Overweight on Cigna, Lowers Price Target to $339

Wall Street is struggling to find risk-on momentum, with major indexes stuck near the flatline at midday as investors assess the latest earnings reports from mega-cap tech stocks and weaker-than-expected U.S. economic growth in the<a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43336153/us-economy-grows-below-q4-estimates-as-consumer-spending-hits-7-quarter-high"> final quarter of 2024.</a>
After Tuesday's rally — which followed a selloff triggered by DeepSeek&#8217;s impact earlier in the week — caution has taken hold, signaling the wounds from the downturn are still fresh.
Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>) is among the hardest-hit stocks, plunging more than 6%, which could mark its worst daily decline<a href="https://www.benzinga.com/news/earnings/25/01/43333060/msft-stock-declines-over-4-in-premarket-after-q2-results-ceo-satya-nadella-says-deepseek-has-some-r"> since October 2022</a>.
Despite reporting overall stronger-than-expected earnings, Microsoft&#8217;s cloud segment, Azure, fell short of growth expectations, and the company slightly missed its revenue guidance for the ongoing quarter.
In contrast, Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) climbed 1.7% post-earnings, reaching new all-time highs.
Another major laggard was United Parcel Service Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>), which plummeted 15%, potentially heading for its worst single-day drop <a href="https://www.benzinga.com/news/earnings/25/01/43335015/ups-q4-earnings-major-customer-volume-cut-raises-jitters-stock-tanks">since going public in 2002</a>.
UPS Chief Financial Officer Brian Dykes revealed during the earnings call the company reached an agreement in principle with Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) to significantly cut the volume of packages it handles for the e-commerce giant, aiming for a 50% reduction by the second half of 2026.
The U.S. dollar and bond yields remained stable following the Federal Reserve's decision Wednesday to keep interest rates unchanged at 4.25%-4.5%.
Among commodities, precious metals stood out, with gold rising 1.4% to <a href="https://www.benzinga.com/news/econ-s/25/01/43348204/gold-hits-record-high-as-central-banks-ease-stance-5-mining-stocks-rally">new all-time highs </a>and silver climbing 2.4%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) edged up 1% to around $105,000.
<h3 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>• Russell 2000</td>
<td>2,306.29</td>
<td>1.0%</td>
</tr>
<tr>
<td>• Dow Jones</td>
<td>44,866.30</td>
<td>0.3%</td>
</tr>
<tr>
<td>• S&amp;P 500</td>
<td>6,054.43</td>
<td>0.3%</td>
</tr>
<tr>
<td>• Nasdaq 100</td>
<td>21,420.81</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:50 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012925&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;inched 0.2% higher to $603.10.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) edged up by 0.2% to $448.22.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;edged 0.1% lower to $521.30.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.2% to $228.50.</li>
<li>The&nbsp;Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, up 1.7%; the&nbsp;Technology Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>), lagged down 0.4%.</li>
</ul>
<h3 class="wp-block-heading">Thursday&#8217;s Stock Movers</h3>
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose 4.4% in reaction to quarterly earnings results. </li>
<li>Other stocks reacting to earnings include:
<ul>
<li>ServiceNow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) down 12.6%</li>
<li>International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) up 12.3%</li>
<li>Lam Research Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) up 7.96%</li>
<li>Raymond James Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) down 1.15%</li>
<li>Ameriprise Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) down 3.08%</li>
<li>Waste Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) up 4.53%</li>
<li>Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) up 10.4%</li>
<li>Lazard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) up 3.58%</li>
<li>Kirby Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEX#NYSE">KEX</a>) up 7.22%</li>
<li>Flagstar Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLG#NYSE">FLG</a>) up 16.46%</li>
<li>Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) down 4.43%</li>
<li>Northrop Grumman Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) down 2.04%</li>
<li>Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) down 6.09%</li>
<li>Valero Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) down 2.5%, </li>
<li>Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) down 8.46%,</li>
</ul>
</li>
<li>Major companies slated to report earnings after the close are Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), KLA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>), PPG Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>), ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) and LPL Financial Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>). </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/25/01/43342224/ryan-cohen-moves-gamestop-shares-to-personal-name-sparking-speculation-on-next-steps">Ryan Cohen Moves 36.8 Million GameStop Shares To Personal Name, Sparking Speculation On Next Steps</a></li>
</ul>
Photo via Shutterstock.

Equities

Commodities

$BTC

AAPL

AMZN

DECK

SPDR Dow Jones Industrial Average ETF Trust

Comments

Cigna

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga